Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Montana: - Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana — Billings, Montana
- Bozeman Health Deaconess Hospital - Bozeman Health Cancer Center — Bozeman, Montana
- Bozeman Health Deaconess Hospital - Bozeman Health Clinical Research — Bozeman, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in Montana: - SCL Health - Montana — Billings, Montana
- SCL Health - Montana — Billings, Montana
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in Montana: - Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Community Medical Center — Missoula, Montana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in Montana: - Research Site — Bozeman, Montana
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in Montana: - Logan Health Research — Kalispell, Montana
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the M…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06116682
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Logan Health Medical Center — Kalispell, Montana
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
- Community Medical Center — Missoula, Montana
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Montana: - Intermountain Health Cancer Centers of Montana — Billings, Montana
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each othe…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06162221
Sites in Montana: - Intermountain Health - St. Vincent Frontier Cancer Center — Billings, Montana
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Montana: - Community Hospital of Anaconda — Anaconda, Montana
- Billings Clinic Cancer Center — Billings, Montana
- Montana Cancer Consortium NCORP — Billings, Montana
- Bozeman Health Deaconess Hospital — Bozeman, Montana
- Benefis Sletten Cancer Institute — Great Falls, Montana
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Montana: - Bozeman Health Deaconess Hospital — Bozeman, Montana